Efficient retrovirus-mediated gene transfer to transplantable human bone marrow cells in the absence of fibronectin

Blood ◽  
2000 ◽  
Vol 96 (7) ◽  
pp. 2432-2439 ◽  
Author(s):  
Burkhard Hennemann ◽  
Il-Hoan Oh ◽  
Jean Y. Chuo ◽  
Christian P. Kalberer ◽  
Patricia D. Schley ◽  
...  

The low frequency of transplantable hematopoietic stem cells in adult human bone marrow (BM) and other differences from cord blood stem cells have impeded studies to optimize the retroviral transduction of stem cells from adult sources. To address this problem, first a cytokine combination was defined that would both maximize the kinetics of adult BM CD34+CD38− cell mitogenesis and minimize the period of prestimulation required for the transduction of these cells by a MSCV-GFP/neor virus in tissue culture dishes in the absence of fibronectin. Three days of stimulation with flt3-ligand, Steel factor, interleukin (IL)-3, and hyper-IL-6 proved both necessary and sufficient to obtain 83% ± 2% GFP+ CD34+CD38− cells, 75% ± 10% G418-resistant clonogenic progenitors, and 50% ± 20% transduced long-term culture-initiating cells as recovered 48 hours after a single exposure to virus. Moreover, this was accompanied by a several-fold increase in viral receptor (pit-1) messenger RNA transcripts in the target cells. Using this prestimulation protocol, repeated daily exposure to new virus (3×) did not alter the proportion of transduced cells over that obtained with a single exposure. Adult human BM cells able to engraft immunodeficient (NOD/SCID-β2M−/−) mice were also efficiently transduced (10%-20% GFP+ human lymphoid and myeloid cells present 6-8 weeks after transplant) using a 6-day prestimulation and infection protocol. A clinically useful efficiency of retrovirus-mediated gene transfer to transplantable adult human BM stem cells can thus be obtained with a protocol that allows their semisynchronous activation into cycle and concomitant increased expression of virus receptor transcripts before virus exposure.

Blood ◽  
2000 ◽  
Vol 96 (7) ◽  
pp. 2432-2439 ◽  
Author(s):  
Burkhard Hennemann ◽  
Il-Hoan Oh ◽  
Jean Y. Chuo ◽  
Christian P. Kalberer ◽  
Patricia D. Schley ◽  
...  

Abstract The low frequency of transplantable hematopoietic stem cells in adult human bone marrow (BM) and other differences from cord blood stem cells have impeded studies to optimize the retroviral transduction of stem cells from adult sources. To address this problem, first a cytokine combination was defined that would both maximize the kinetics of adult BM CD34+CD38− cell mitogenesis and minimize the period of prestimulation required for the transduction of these cells by a MSCV-GFP/neor virus in tissue culture dishes in the absence of fibronectin. Three days of stimulation with flt3-ligand, Steel factor, interleukin (IL)-3, and hyper-IL-6 proved both necessary and sufficient to obtain 83% ± 2% GFP+ CD34+CD38− cells, 75% ± 10% G418-resistant clonogenic progenitors, and 50% ± 20% transduced long-term culture-initiating cells as recovered 48 hours after a single exposure to virus. Moreover, this was accompanied by a several-fold increase in viral receptor (pit-1) messenger RNA transcripts in the target cells. Using this prestimulation protocol, repeated daily exposure to new virus (3×) did not alter the proportion of transduced cells over that obtained with a single exposure. Adult human BM cells able to engraft immunodeficient (NOD/SCID-β2M−/−) mice were also efficiently transduced (10%-20% GFP+ human lymphoid and myeloid cells present 6-8 weeks after transplant) using a 6-day prestimulation and infection protocol. A clinically useful efficiency of retrovirus-mediated gene transfer to transplantable adult human BM stem cells can thus be obtained with a protocol that allows their semisynchronous activation into cycle and concomitant increased expression of virus receptor transcripts before virus exposure.


2003 ◽  
Vol 31 (5) ◽  
pp. 406-412 ◽  
Author(s):  
Esmail D Zanjani ◽  
Graça Almeida-Porada ◽  
Anne G Livingston ◽  
HaiQun Zeng ◽  
Makio Ogawa

Blood ◽  
2002 ◽  
Vol 100 (13) ◽  
pp. 4433-4439 ◽  
Author(s):  
John P. Chute ◽  
Abha A. Saini ◽  
Dennis J. Chute ◽  
Mark R. Wells ◽  
William B. Clark ◽  
...  

Adult human bone marrow (ABM) is an important source of hematopoietic stem cells for transplantation in the treatment of malignant and nonmalignant diseases. However, in contrast to the recent progress that has been achieved with umbilical cord blood, methods to expand ABM stem cells for therapeutic applications have been disappointing. In this study, we describe a novel culture method that uses human brain endothelial cells (HUBECs) and that supports the quantitative expansion of the most primitive measurable cell within the adult bone marrow compartment, the nonobese diabetic/severe combined immunodeficient (NOD/SCID) repopulating cell (SRC). Coculture of human ABM CD34+ cells with brain endothelial cells for 7 days supported a 5.4-fold increase in CD34+ cells, induced more than 95% of the CD34+CD38− subset to enter cell division, and produced progeny that engrafted NOD/SCID mice at significantly higher rates than fresh ABM CD34+ cells. Using a limiting dilution analysis, we found the frequency of SRCs within fresh ABM CD34+ cells to be 1 in 9.9 × 105 cells. Following HUBEC culture, the estimated frequency of SRCs increased to 1 in 2.4 × 105cells. All mice that received transplants of HUBEC-cultured cells showed B-lymphoid and myeloid differentiation, indicating that a primitive hematopoietic cell was preserved during culture. Noncontact HUBEC cultures also maintained SRCs at a level comparable to contact HUBEC cultures, suggesting that cell-to-cell contact was not required. These data demonstrate that human brain endothelial cells possess a unique hematopoietic activity that increases the repopulating capacity of adult human bone marrow.


Cytotherapy ◽  
2015 ◽  
Vol 17 (6) ◽  
pp. S37
Author(s):  
Cécile Coste ◽  
Virginie Neirinckx ◽  
Anil Sharma ◽  
Bernard Rogister ◽  
François Lallemend ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Yi Sun ◽  
Yuke Tian ◽  
Haifeng Li ◽  
Dengwen Zhang ◽  
Qiang Sun

Background. This study aimed to investigate the use of human bone marrow mesenchymal stem cells (hBMSCs) genetically engineered with the human proenkephalin (hPPE) gene to treat bone cancer pain (BCP) in a rat model.Methods. Primary cultured hBMSCs were passaged and modified with hPPE, and the cell suspensions (6 × 106) were then intrathecally injected into a rat model of BCP. Paw mechanical withdrawal threshold (PMWT) was measured before and after BCP. The effects of hPPE gene transfer on hBMSC bioactivity were analyzed in vitro and in vivo.Results. No changes were observed in the surface phenotypes and differentiation of hBMSCs after gene transfer. The hPPE-hBMSC group showed improved PMWT values on the ipsilateral side of rats with BCP from day 12 postoperatively, and the analgesic effect was reversed by naloxone. The levels of proinflammatory cytokines such as IL-1βand IL-6 were ameliorated, and leucine-enkephalin (L-EK) secretion was augmented, in the hPPE-engineered hBMSC group.Conclusion. The intrathecal administration of BMSCs modified with the hPPE gene can effectively relieve pain caused by bone cancer in rats and might be a potentially therapeutic tool for cancer-related pain in humans.


2008 ◽  
Vol 15 (9) ◽  
pp. 553-562 ◽  
Author(s):  
I A W Ho ◽  
K Y W Chan ◽  
L Miao ◽  
W S N Shim ◽  
C M Guo ◽  
...  

2003 ◽  
Vol 12 (6) ◽  
pp. 681-688 ◽  
Author(s):  
Alexis Joannides ◽  
Phil Gaughwin ◽  
Mike Scott ◽  
Suzanne Watt ◽  
Alastair Compston ◽  
...  

PLoS ONE ◽  
2010 ◽  
Vol 5 (7) ◽  
pp. e11803 ◽  
Author(s):  
Federica Collino ◽  
Maria Chiara Deregibus ◽  
Stefania Bruno ◽  
Luca Sterpone ◽  
Giulia Aghemo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document